The document contains 17 questions and answers about International Council for Harmonization (ICH) guidelines. Some key points covered include:
- ICH guidelines are divided into 4 main categories: Quality, Safety, Efficacy, and Multidisciplinary. The Multidisciplinary section includes 15 subsections.
- The M2 guideline establishes standards for electronic transfer of regulatory information and was agreed to in 1994.
- The M13 guideline provides recommendations for assessing bioequivalence during drug development and approval.
The document contains 17 questions and answers about International Council for Harmonization (ICH) guidelines. Some key points covered include:
- ICH guidelines are divided into 4 main categories: Quality, Safety, Efficacy, and Multidisciplinary. The Multidisciplinary section includes 15 subsections.
- The M2 guideline establishes standards for electronic transfer of regulatory information and was agreed to in 1994.
- The M13 guideline provides recommendations for assessing bioequivalence during drug development and approval.
Original Title
Quiz-Questions with Answers_ICH - Multidisciplinary Guidelines_Anurag
The document contains 17 questions and answers about International Council for Harmonization (ICH) guidelines. Some key points covered include:
- ICH guidelines are divided into 4 main categories: Quality, Safety, Efficacy, and Multidisciplinary. The Multidisciplinary section includes 15 subsections.
- The M2 guideline establishes standards for electronic transfer of regulatory information and was agreed to in 1994.
- The M13 guideline provides recommendations for assessing bioequivalence during drug development and approval.
The document contains 17 questions and answers about International Council for Harmonization (ICH) guidelines. Some key points covered include:
- ICH guidelines are divided into 4 main categories: Quality, Safety, Efficacy, and Multidisciplinary. The Multidisciplinary section includes 15 subsections.
- The M2 guideline establishes standards for electronic transfer of regulatory information and was agreed to in 1994.
- The M13 guideline provides recommendations for assessing bioequivalence during drug development and approval.
Download as DOCX, PDF, TXT or read online from Scribd
Download as docx, pdf, or txt
You are on page 1of 3
Quiz-Questions with Answers
Q.1- What do you understand by Multidisciplinary guidelines? And in how
many sections it is divided. Ans 1. Those are the cross-cutting topics which do not fit uniquely into one of the Quality, Safety and Efficacy categories. It includes the ICH medical terminology (MedDRA), the Common Technical Document (CTD) and the development of Electronic Standards for the Transfer of Regulatory Information (ESTRI). It includes total 15 sections. Q.2-Four categories of ICH guidelines are _________. Ans 2- Four categories are- Quality, Safety, Efficacy and Multidisciplinary. Q.3- What do you understand by M2 guidelines and in which year it was established and with what objective? Ans 3- The M2 guideline is EWG Electronic standards for the transfer of Regulatory Information and it was established by the ICH Steering Committee in 1994 with the objective of facilitating international electronic communication by evaluating and recommending, open and non-proprietary - to the extent possible - Electronic Standards for the Transfer of Regulatory Information (ESTRI) that will meet the requirements of the pharmaceutical companies and regulatory authorities. Q.4- All eCTD submissions include ________ and it identifies following information ____________. Ans 4- Module 1 and and it identifies following information-1. Company name 2. Drug name 3. Submission Type 4. Submission date 5. Application number 6. Sequence Number Q.5- M9 Biopharmaceutics Classification System (BCS) endorsed by the ICH Assembly in __________. Ans 5- October 2016 Q.6- The MedDRA (Medical Dictionary for Regulatory Activities) terminology was launched in _______________________. Ans-6- 1999 Q.7- What are the file formats that can be included in eCTD. Ans 7- The files formats that can be included in the eCTD are portable document format (PDF) and XML. Q.8- In _______________, the ICH Steering Committee endorsed a Concept Paper for Topic M5 and subsequently formed the M5 EWG to develop ICH requirements for the standardization of medicinal product identifiers and related terminology. Ans 8- November 2003 Q.9- The Common Technical Document was agreed upon by the Steering Committee in ___________. Ans 9- November 2000 Q.10- The development of a Medical Dictionary for Regulatory Activities (MedDRA) was approved by the ___________ in ___________. Ans 10- ICH Steering Committee, 1997 Q. 11-What is objective of ICH? Ans-ICH aims to achieve greater harmonisation worldwide for the development and approval of safe, effective, and high-quality medicines in the most resource-efficient manner. Q 12- What is viral shedding in gene therapy? Viruses are the most commonly used vectors for clinical gene therapy. The risk of dissemination of a viral vector into the environment via excreta from the treated patient, a phenomenon called shedding, is a major safety concern for the environment.
Ans-This topic was endorsed by the ICH Management Committee in October 2016. • This new multidisciplinary guideline will apply to the validation of bioanalytical methods and study sample analyses in non-clinical and clinical studies. • This guideline will provide recommendations on the scientific regulatory requirements for bioanalysis conducted during the development of drugs of both chemical and biological origins. • It will also address issues on method validation by considering the characteristics of the analytical methods used in bioanalysis, e.g., chromatographic assay and ligand binding assay.
Q 14. Explain M9 Biopharmaceutics Classification System (BCS)-based
biowaivers Guideline. Ans- This topic was endorsed by the ICH Assembly in October 2016. This new multidisciplinary Guideline is proposed to address Biopharmaceutics Classification System (BCS)-based biowaivers. • BCS-based biowaivers may be applicable to BCS Class I and III drugs, however BCS-based biowaivers for these two classes are not recognised worldwide. • This Guideline applies to the systems supporting the development and manufacture of pharmaceutical drug substances and drug products, including biotechnology and biological products. • This Guideline will provide recommendations to support the biopharmaceutics classification of medicinal products and will provide recommendations to support the waiver of bioequivalence studies. Q 15. What is M10 testing? Ans- The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) is in the process of revising M10, a multidisciplinary guideline that governs bioanalytical method validation. Drugs need to contain the correct concentrations of therapeutic products to be effective and safe. Q 16. What are the 3 types of drug interactions? Ans- Drug-drug interaction: A reaction between two (or more) drugs. • Drug-food interaction: A reaction between a drug and a food or beverage. • Drug-condition interaction: A reaction that occurs when taking a drug while having a certain medical condition.
Q 17. Explain ICH M13: Bioequivalence guidelines.
Ans- Supporting early-stage regulatory change-control, ie, changing the product type during early clinical development. • Supporting the use of blinding strategies in pivotal clinical studies, eg, the use of over-encapsulated comparator products.